Issue link: http://osercommunicationsgroup.uberflip.com/i/499815
C h a i n D r u g s t o r e D a i l y M o n d a y, A p r i l 2 7 , 2 0 1 5 8 TRIUMPH PHARMACEUTICAL CEO EXPLAINS BAD BREATH An interview with President and CEO of Triumph Pharmaceutical, Andrew Burch. CDD: What causes bad breath? AB: The creation of bad breath is a nat- ural and ongoing process in our mouths each day. There are millions of germs in our mouths, which break down protein particles that are always present in our saliva. This results in the production of foul smelling sulfur gas. This gas is what we perceive as embarrassing bad breath. CDD: So is bad breath mostly a cosmet- ic issue? AB: Not just a cosmetic issue, bad breath is a social taboo that can interfere with every relationship, and the problem is virtually universal. Everyone has expe- rienced it in the form of morning breath and at least one in four people suffer from a more serious bad breath problem. CDD: What is the solution for bad breath? AB: Most of the so-called bad breath cures only mask bad breath or provide you with a temporary fix, lasting only five minutes, or up to 60 minutes max. To get all day fresh clean breath, you first have to understand the cause of bad breath. The only answer to eliminating and preventing bad breath long term is SmartMouth Mouthwash, for clinically proven 12-hour fresh breath. SmartMouth Mouthwash uses a patented zinc-ion technology to eliminate existing bad breath and prevent it from coming back for at least 12 hours. SmartMouth Mouthwash's patented, dual-solution technol- ogy requires two key solutions to be kept separate until just prior to rins- ing. This ensures that SmartMouth is freshly activated with each use to pro- vide unmatched, all day fresh breath. Currently, each SmartMouth Mouthwash purchase comes with two bottles of liq- uid that are mixed at the time of use. However, starting mid-summer 2015, the two solutions will be poured and activat- ed from a dual-bottle, single-pour deliv- ery system with a patented dual pour spout. No more boxes, one beautiful bot- tle and no more pumps! CDD: Why Does SmartMouth offer two different formulas? AB: Two formulas are available: the original formula and Advanced Clinical Formula. "Young people, mostly under 40, are using the origi- nal formula because their focus is on 12 hours of clean fresh breath most- ly for personal hygiene and social reasons. Middle aged and older adults tend to choose the Gums and Plaque formula to have 12-hour fresh breath plus anti-plaque and anti-gingivi- tis benefits. Consumer sales of the two are actually pretty even. The idea though is that everyone that purchases SmartMouth wants 24 hours of clean fresh breath (two daily rinses). But some consumers want that 'plus' factor where they also get the full clinical benefits to protect gums along with fighting plaque. For more information, contact Andrew Burch, President, at 314.882.2610 or Aburch@smartmouth.com or visit online at www.smartmouth.com. MALLINCKRODT SPECIALTY GENERICS CONTINUES TO REDEFINE BIOPHARMACEUTICALS For nearly 150 years, the Mallinckrodt name has represented quality products, business integrity, and service to patients, customers and the communities. Its vision and dedication to improving lives is matched only by the distinct approach to managing the complex situations of the field. As an independent global biopharma- ceutical company focused on controlled substances, autoimmune and rare dis- eases, acute care and diagnostic medical imaging, Mallinckrodt Pharmaceuticals continues to provide unmet value for physicians and patients. The common thread critical to its past and future success is its strong abili- ty to master and manage complexity. Simply put, Mallinckrodt Pharmaceuticals strives to make the com- plex simple. Driven by an intense energy and led by about 5,500 engaged and high- performing people, this forward momen- tum pushes it to be a top-performing spe- cialty biopharmaceutical company. Mallinckrodt Specialty Generics business developed as a natural extension of the company's acetaminophen raw materials business. Many of the generic products use the sifted acetaminophen produced by Mallinckrodt's Active Pharmaceuticals Ingredients business to ensure a reliable source and quality of supply. Mallinckrodt saw potential in the generics business and decided to pursue manufacturing its own tablets. Today, its Specialty Generics busi- ness offers a comprehensive product portfolio with industry-leading expertise across pain management, ADHD and addiction treatment. More than 80 mil- lion prescriptions are filled annually with Mallinckrodt's generic products, accord- ing to the IMS Health National Sales Perspective along with being one of the nation's largest pro- ducers of controlled opioid pain medications and one of the world's leading producers of bulk aceta- minophen. And according to the July 2014 National Analytics, its top eight generic products each hold top three mar- ket share for their respective categories. Employing a vertically integrated process to ensure quality during every step of development from active ingredi- ent processing through formulation, man- ufacturing and distribution, Mallinckrodt Pharmaceuticals' ability to manufacture complex products and deliver them effi- ciently to customers reflects the values of quality, integrity and service. The goal of providing high-quality, innovative products that began almost 150 years ago with the Mallinckrodt brothers still persists today. Mallinckrodt Pharmaceuticals has had a highly pro- ductive R&D team, historically, with FDA approval of 12 new products since 2010. The company's development pipeline is focused in areas where the company can bring differentiated value to the marketplace. Investment in infra- structure and capacity improvements allow it to consistently deliver the high quality products customers need. Recent expan- sion of the high volume manufacturing facility in Hobart, N.Y., will increase pro- duction of generic pharmaceuticals, and new packaging lines will improve prod- uct output along with investment in Mallinckrodt's API business to increase capacity and reliability of raw materials for generic pharmaceuticals. The company has invested millions of dollars in research efforts focusing on exploring the abuse-deterrent poten- tial of its proprietary formulation tech- nologies. Developing abuse-deterrent technologies that can be used in both branded and generic medicines will make products less attractive to poten- tial abusers, while providing patients with a wide range of safe, affordable options. For more information, visit booth #318 or go online to www.mallinckrodt.com or call 314.654.2000. INCREASING THE ROLE OF PHARMACISTS IN INTERDISCIPLINARY HEALTHCARE TEAMS By Ned Milenkovich, Principal with Much Shelist. In January 2015, the National Governors Association (NGA) released the white paper, "The Expanding Role of Pharmacists in a Transformed Health Care System," challenging states to change their laws to allow pharmacists to become more integrated into the health care delivery system. The NGA, along with health care experts, acknowledges the essential role that medication manage- ment plays in treating chronic diseases and stresses that including pharmacists on chronic care delivery teams will improve health outcomes and reduce costs. The Pharmacist's Role The healthcare system is experiencing a fundamental shift in the areas of finance and delivery of healthcare services. States are considering laws, regulations and best practices to improve outcomes while reducing costs. This is partly due to a growing number of adults who have chronic diseases and the multiple med- ications required for treatment. As these rates increase, so does non-adherence to the proper medication regimen, the con- sequences of which are both physical and monetary in nature. Pharmacists have the capabilities to play a large role in shaping health care delivery to individuals, especially those with chronic diseases. Medication manage- ment therapy, wellness counseling, disease prevention services and primary care are most effective when the pharmacist is included in the larger interdisciplinary team. This can be documented through collaborative practice agreements (CPAs), which stream- line patient care and allow licensed providers to refer patients to a pharmacist for corresponding healthcare services. This integra- tion also allows for a patient's entire healthcare team to collaborate and maintain transparency, increasing the qual- ity of both individual health care services as well as the entire patient health care plan. Obstacles Several barriers distance pharmacists from fully integrating into the healthcare delivery system and prevent them from providing direct patient care services, including Restrictive laws and regula- tions governing CPAs with some states requiring separate CPAs for each patient, stifling the efficiency of the process. The failure to appropriately compen- sate or reimburse pharmacists for direct patient care services is another so that integrating pharmacists will also require recognition by third party payors in order for the cost structure to reflect the needs of both patients and healthcare providers. Many states and private healthcare plans, for example, still have limits on pharmacists who wish to bill directly for their services. This acts as a deterrent for both pharmacists and patients. The last are the limitations on the access to health IT systems. Access to health IT systems is essential to the phar- macist's role in a collaborative healthcare team. One of the largest obstacles in cre- ating this transparency is tied to state laws and their failure to recognize phar- macists as providers. As our healthcare system continues to take steps to increase the quality and lower costs associated with healthcare, it is important to recognize the value that phar- macists can add and to adopt laws, regula- tions and policies that allow and encourage interdisciplinary healthcare teams. For more information, contact Ned at 312.521.2482 or at nmilenkovich@ muchshelist.com.